Articles From: Endo Receives Final Approval for Generic Version of Valcyte® to Endurance International Group to Present at the Credit Suisse 18th Annual Technology Conference


DUBLIN , Nov.
Sign-up for Endo Receives Final Approval for Generic Version of Valcyte® investment picks
Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC Canada NewsWire DUBLIN , Dec.
Sign-up for Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC investment picks
- Total quarterly revenues of $764 million, reported diluted (GAAP) loss per share of $1.64 and adjusted diluted EPS of $1.15. - Strong financial results driven by combination of solid growth from the base business and the completion of multiple accretive acquisitions over the past year.
Sign-up for Endo Reports Third Quarter Financial Results investment picks
- Auxilium Shareholders to Receive $33.25 Per Share - Combination Designed to Create Leading Specialty Healthcare Company with Expanded Platform for Future Growth - Addition of Auxilium's Leading Men's Health Products and Development Portfolio Expected to Significantly Enhance Endo's Branded Pharmaceutical Business - Transaction Expected to be Immediately Accretive - Endo Expects to Generate up to $175 Million of Annual Run Rate Operating Expense Reductions Inclusive of the $75 Million of Reductions Previously Announced by Auxilium DUBLIN and CHESTERBROOK, Pa.
Sign-up for Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion investment picks
By Chelsey Dulaney Endo International PLC on Thursday said it has agreed to buy Auxilium Pharmaceuticals Inc. in a cash-and-stock deal valued at about $2.6 billion, after the Dublin-based company's $2.2 billion offer for Auxilium was rejected last month.
Sign-up for Endo to buy Auxilium in $2.6 billion deal investment picks
Endo International (ENDP) said Monday it believes its buyout offer for Auxilium Pharmaceuticals' (AUXL) is "compelling," and provides a "substantial premium and immediate cash value" for Auxilium shareholders.
Sign-up for Endo: Buyout offer for Auxilium 'compelling,' provides 'substantial premium' investment picks
WEST LAFAYETTE, Ind., Oct.
Sign-up for Endocyte Announces Third Quarter 2014 Earnings Conference Call investment picks
Folate-targeted EC1456 with Potent Tubulysin Payload Now at Higher Phase 1 Dose Level than Vintafolide WEST LAFAYETTE, Ind., Nov.
Sign-up for Endocyte Reports Third Quarter Financial Results and Provides Clinical Update investment picks
WEST LAFAYETTE, Ind., Nov.
Sign-up for Endocyte to Present at the 2014 Credit Suisse Healthcare Conference investment picks
IRVINE, Calif., Sept.
Sign-up for Endologix Announces Preliminary Third Quarter 2014 Revenue and Updates Financial Guidance investment picks
IRVINE, Calif., Sept.
Sign-up for Endologix Completes Enrollment in EVAS FORWARD - Global Registry investment picks
IRVINE, Calif., Nov.
Sign-up for Endologix Completes Patient Enrollment in the Nellix(R) EVAS FORWARD-IDE Clinical Trial investment picks
IRVINE, Calif., Oct.
Sign-up for Endologix Reports 12% Global Revenue Growth for the Third Quarter 2014 investment picks
IRVINE, Calif., Nov.
Sign-up for Endologix to Host Investor Meeting on Thursday, November 20, 2014 investment picks
LEOPARD Study to Enroll 600 Patients to Provide a "Real-World" Head-to-Head Comparison of the AFX® System Versus Other Commercially Available EVAR Devices IRVINE, Calif., Sept.
Sign-up for Endologix to Initiate First Ever Comparative Randomized EVAR Study investment picks
IRVINE, Calif., Nov.
Sign-up for Endologix to Participate in Three Investor Conferences in November investment picks
IRVINE, Calif., Nov.
Sign-up for Endologix to Participate in Two Investor Conferences in December investment picks
IRVINE, Calif., Oct.
Sign-up for Endologix to Report Third Quarter 2014 Financial Results on October 30, 2014 investment picks
http://media.marketwire.com/attachments/201401/219160_Endonovo_Logo_Redcopy.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162389&ProfileId=051205&sourceType=1 LOS ANGELES, CA --
Sign-up for Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment investment picks
Unruh's New Role will Focus on International Expansion into Emerging Markets BURLINGTON, Mass.
Sign-up for Endurance Announces Brian Unruh as Executive Vice President, International Operations and Jason Miner as General Manager of Domain-Focused Brands investment picks
Bluehost, FatCow and A Small Orange to Raise Money for Local and National Charities BURLINGTON, Mass.
Sign-up for Endurance Gives Back During the Month of October investment picks
BURLINGTON, Mass., Nov.
Sign-up for Endurance International Group Announces Completion of Public Offering investment picks
Talent is needed in Houston, Texas and Orem, Utah for HostGator and Bluehost BURLINGTON, Mass.
Sign-up for Endurance International Group Is Hiring investment picks
BURLINGTON, Mass., Nov.
Sign-up for Endurance International Group Prices Public Offering of 13,000,000 Shares of Common Stock investment picks
BURLINGTON, Mass., Nov.
Sign-up for Endurance International Group Reports 2014 Third Quarter Results investment picks
BURLINGTON, Mass., Oct.
Sign-up for Endurance International Group to Announce 2014 Third Quarter Financial Results on November 4, 2014 investment picks
BURLINGTON, Mass., Nov.
Sign-up for Endurance International Group to Present at the Credit Suisse 18th Annual Technology Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Endo Receives Final Approval for Generic Version of Valcyte® to Endurance International Group to Present at the Credit Suisse 18th Annual Technology Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent